Biohaven (NYSE:BHVN) Capex-to-Revenue

: 0.00 (As of Sep. 2022)

View and export this data going back to 2022. Start your Free Trial

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Biohaven's Capital Expenditure for the three months ended in Sep. 2022 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2022 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Biohaven Capex-to-Revenue Historical Data

The historical data trend for Biohaven's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Annual Data

Trend

Dec20

Dec21

Capex-to-Revenue

Biohaven Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22
Capex-to-Revenue		-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Biohaven's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Biohaven Capex-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Biohaven's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biohaven's Capex-to-Revenue falls in comparison to its industry or sector. The grey bar indicates the Capex-to-Revenue's extreme value range as defined by GuruFocus.

Biohaven Capex-to-Revenue Calculation

Biohaven's Capex-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.938)	/	0
	=	N/A

Biohaven's Capex-to-Revenue for the quarter that ended in Sep. 2022 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Biohaven (NYSE:BHVN) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Biohaven Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biohaven's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Biohaven (NYSE:BHVN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Ltd (NYSE:BHVN) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.

Executives

Robert J Hugin	director	C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Julia P Gregory	director	8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Gregory Bailey	director	4 A CHESHAM STREET LONDON X0 SW1X8DT
Kimberly Gentile	officer: SVP, Clinical Operations	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
John W Childs	director	111 HUNTINGTON AVENUE SUITE 2900 BOSTON MA 02199
Vlad Coric	director, officer: Chief Executive Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Irina Antonijevic	director	215 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten	officer: Chief Financial Officer	215 CHURCH STREET NEW HAVEN CT 06510
Kishan Mehta	director	540 WEST 49TH STREET UNIT# PH1N NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd.	10 percent owner	215 CHURCH STREET NEW HAVEN CT 06510
Bruce Car	officer: Chief Scientific Officer	AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139